Սպնիբ 100 մգ Դասատինիբ դեղահաբեր (1 շիշ / 30 դեղահաբ)

Buy Spnib 100 mg Dasatinib Tablets Online

Սպնիբ 100 մգ Դասատինիբ դեղահաբեր (1 շիշ / 30 դեղահաբ)

Մի հայացքով

Ընդհանուր անվանում՝ Dasatinib

Բրենդի անվանումը՝ Սպնիբ 100 մգ

Հզորությունը և փաթեթի չափը՝ 100 mg tablets, 1 bottle / 30 tablets

Դեղաչափի ձևը և ընդունման եղանակը. Oral film-coated tablets for swallowing whole with water

Թերապևտիկ դաս. Second-generation BCR-ABL թիրոզին կինազի ինհիբիտոր and SRC family kinase inhibitor

Հիմնական ցուցումներ՝ Philadelphia chromosome–positive քրոնիկ միելոիդ լեյկեմիա (ՔՄԼ) և Ph+ սուր լիմֆոբլաստային լեյկոզ (ALL), ըստ տեղական պիտակի

Բնորոշ կիրառություն թերապիայի մեջ. Used as first- or subsequent-line TKI option in Ph+ CML or Ph+ ALL under specialist protocols

Գործողության եղանակը՝ Արգելափակում է BCR-ABL and other kinases to block abnormal signalling and leukemic cell proliferation

Հիմնական առավելությունները՝ Active in many patients resistant or intolerant to imatinib, with rapid and deep molecular responses in appropriately selected cases

Նախազգուշական միջոցներ: Myelosuppression, bleeding, fluid retention, pulmonary arterial hypertension and QT prolongation require close monitoring

Պահեստավորում՝ Store below 25 °C in the original container, tightly closed and protected from moisture

Արտադրանքի նկարագրություն

Սպնիբ 100 մգ պարունակում է դասատինիբ, an oral second-generation թիրոզին կինազի արգելակիչ used in the treatment of Philadelphia chromosome–positive leukemias. It is typically prescribed for Ph+ քրոնիկ միելոիդ լեյկեմիա (ՔՄԼ) և Ph+ սուր լիմֆոբլաստային լեյկոզ (ALL) in adults when a potent BCR-ABL արգելակիչ is needed, including situations where իմատինիբ has failed due to resistance or intolerance, or where local protocols support dasatinib in earlier lines of therapy.

Each bottle of Սպնիբ 100 մգ մատակարարված է Ջեներիկ դեղերի շուկա contains 30 film-coated dasatinib tablets. The 100 mg strength is commonly used in adult regimens, although the exact dose and schedule are always determined by a hematologist or oncologist based on disease phase, prior treatment, concomitant medicines and the patient’s overall health. Spnib 100 mg dasatinib tablets are taken by mouth, usually once daily, and are intended for long-term use as part of a continuous թիրոզին կինազի արգելակիչ strategy for Ph+ CML or Ph+ ALL where clinically appropriate.

Ջեներիկ դեղերի շուկա works only with licensed manufacturers and authorised distributors for oncology TKIs like Սպնիբ 100 մգ. Bottles are supplied in original, sealed packaging so that treating centres can verify brand, strength, batch number and expiry before dispensing. Outer shipping cartons are neutral, without visible references to leukemia or dasatinib, helping to protect patient privacy during international delivery. Prices are displayed in ԱՄՆ դոլար to make long-term therapy planning more transparent for patients and clinics.

Հիմնական կիրառություններ

Spnib 100 mg dasatinib tablets are used for guideline-based indications in Philadelphia chromosome–positive leukemias, according to local product information and specialist recommendations. In clinical practice, this typically includes:

Սպնիբ 100 մգ as a second-generation BCR-ABL արգելակիչ in adults with Ph+ CML, including chronic, accelerated or blast phase disease where dasatinib is considered appropriate by the treating team.

Սպնիբ 100 մգ in adults with Ph+ ALL when a potent oral TKI is required in induction, consolidation or maintenance phases alongside multi-agent chemotherapy or other targeted regimens, based on protocol.

Depending on region and label, դասատինիբ may be used either after imatinib failure or intolerance, or as a first-line option in selected patients. The decision to use Սպնիբ 100 մգ, and its position relative to other TKIs such as imatinib or nilotinib, must always be made by an experienced hematologist working within evidence-based guidelines.

Ինչպես է դասատինիբը գործում քիմիաթերապիայի մեջ

Dasatinib, ակտիվ բաղադրիչը Սպնիբ 100 մգ, is a potent inhibitor of the BCR-ABL tyrosine kinase, the abnormal fusion protein generated by the Philadelphia chromosome translocation t(9;22). This fusion kinase drives uncontrolled proliferation and survival of leukemic cells in Ph+ CML and Ph+ ALL.

By binding to and inhibiting BCR-ABL, դասատինիբ blocks downstream signalling pathways that support leukemic cell division and resistance to apoptosis. Dasatinib also inhibits other kinases, including members of the SRC family, which may contribute to its activity in leukemic cells. Compared with first-generation TKIs, dasatinib has broader binding characteristics and can retain activity against many imatinib-resistant BCR-ABL mutations, although some mutations remain problematic.

In clinical use, effective inhibition of BCR-ABL by Spnib 100 mg dasatinib tablets can lead to rapid reductions in leukocyte counts, improved bone marrow morphology and achievement of cytogenetic and molecular responses. Achieving and maintaining deep molecular responses is associated with better long-term outcomes in Ph+ CML and Ph+ ALL when managed according to specialist protocols.

Դեղաչափ և կիրառում

Սպնիբ 100 մգ must be prescribed and monitored by a hematologist or oncologist experienced in managing Ph+ leukemias. The usual adult dose and schedule are defined in the official product information and may vary according to indication, disease phase, prior therapies and local practice. Tablets are swallowed whole with water and should not be crushed or chewed.

Dasatinib can be taken with or without food, but patients should follow the exact instructions given by their treatment centre. Certain medicines, including proton pump inhibitors and strong CYP3A4 inhibitors or inducers, can affect dasatinib exposure and may need to be avoided or adjusted. Regular blood counts, liver function tests and clinical assessments are required to monitor response and toxicity. Dose interruptions, reductions or switches to an alternative TKI may be necessary in cases of significant myelosuppression, fluid retention, pulmonary events or other adverse effects. Patients should never change their Սպնիբ 100 մգ dose without specialist advice.

Նախազգուշական միջոցներ

Մինչև սկսելը Spnib 100 mg dasatinib tablets, the treatment team will review the patient’s medical history, ECG, cardiovascular status, liver and kidney function, concomitant medicines and bleeding risk. Dasatinib can cause myelosuppression, including neutropenia, thrombocytopenia and anemia, so frequent full blood count monitoring is essential, particularly in the first months of therapy.

Important precautions described in dasatinib prescribing information include risks of serious bleeding, fluid retention (such as pleural effusion and pericardial effusion), pulmonary arterial hypertension, QT interval prolongation and hepatotoxicity. Caution is required in patients with prior heart disease, uncontrolled hypertension, lung disease, liver impairment or those taking other QT-prolonging drugs. Women who are pregnant or may become pregnant should not handle dasatinib tablets without protection, and effective contraception is recommended for patients of reproductive potential.

Դասատինիբի կողմնակի ազդեցությունները

Հաճախակի կողմնակի ազդեցություններ

Ընդհանուր դասատինիբի կողմնակի ազդեցությունները հիվանդների մոտ, որոնք ընդունում են Սպնիբ 100 մգ include myelosuppression with low white cells, low platelets or anemia; headache; fatigue; nausea; vomiting; diarrhoea; abdominal discomfort; rash; musculoskeletal pain; mild fluid retention such as ankle swelling; and mild elevations in liver enzymes. Some patients experience cough or shortness of breath, which may be related to fluid around the lungs and must be assessed by the treating team.

These effects are often manageable with temporary treatment interruption, dose reduction, supportive therapy such as transfusions or growth factors and careful monitoring. Patients should attend all scheduled blood tests and clinic visits so that emerging issues can be detected early.

Լուրջ կողմնակի ազդեցություններ

Լուրջ Դասատինիբի կողմնակի ազդեցությունները require urgent medical attention. These may include severe thrombocytopenia or neutropenia with increased risk of bleeding or infection; major haemorrhage; significant pleural or pericardial effusion; signs of թոքային զարկերակային գերճնշում such as progressive shortness of breath and fatigue; marked fluid overload; severe liver injury with jaundice; and serious cardiac events or marked QT prolongation.

Patients should contact emergency services or their treating centre immediately if they experience chest pain, severe shortness of breath, sudden swelling, black or bloody stools, coughing up blood, high fever, uncontrolled bleeding, confusion, severe dizziness or fainting. The treating team may need to interrupt Սպնիբ 100 մգ, adjust the dose or switch to an alternative therapy depending on the severity and type of adverse event.

Պահեստավորում

Spnib 100 mg dasatinib tablets should be stored in the original, tightly closed bottle below 25 °C, protected from moisture and heat. The bottle should be kept out of the sight and reach of children and should not be stored in very humid environments such as bathrooms. Tablets must not be used after the expiry date shown on the label and carton. Unused or expired tablets should be returned to a pharmacy or disposed of in accordance with local oncology waste guidelines, not placed in household rubbish or wastewater.

Ինչու՞ գնել Ջեներիկ Մեդս Մարթից

Ջեներիկ դեղերի շուկա is focused on structured access to specialist oral oncology medicines such as Spnib 100 mg dasatinib tablets. We source only from licensed manufacturers and authorised distributors who comply with Good Manufacturing Practice and maintain traceable batch records. Each bottle of Սպնիբ 100 մգ is supplied in sealed, original packaging so pharmacists and clinicians can verify brand name, strength, batch number and expiry before dispensing to patients.

Orders placed through Ջեներիկ դեղերի շուկա are billed in ԱՄՆ դոլար, simplifying cost planning for long-term TKI therapy. Shipments are packed in neutral outer cartons with no explicit mention of leukemia, dasatinib or Սպնիբ 100 մգ, and where available, tracking information is provided so that patients and clinics can coordinate refills before existing supplies run out. Our support team can help with ordering and logistics questions, while all decisions about whether to use a specific թիրոզին կինազի արգելակիչ remain exclusively with your hematology or oncology team.

Պատվիրեք հիմա

Spnib 100 mg dasatinib tablets are a potent, targeted therapy for Philadelphia chromosome–positive leukemias and must not be started without a detailed plan from an experienced specialist. Before you buy Spnib 100 mg online -ից Ջեներիկ դեղերի շուկա, ensure that your diagnosis, BCR-ABL status, prior TKI exposure and overall treatment goals have been fully discussed with your hematologist. You should have clear instructions about your daily dose, timing, monitoring schedule and what to do if doses are missed or side effects occur.

Once your plan is in place, your team can calculate how many bottles of Spnib 100 mg (1 bottle / 30 tabs) are needed for the initial treatment period. You can then select the appropriate quantity on Ջեներիկ դեղերի շուկա, ավելացրեք այն ձեր զամբյուղին և ավարտեք անվտանգ վճարումը ԱՄՆ դոլար. Your medicine will be shipped in discreet packaging with full product labelling. You should never change, pause or stop դասատինիբով թերապիա on your own; any new or severe symptoms must be discussed promptly with your specialist team, and emergency services should be contacted when serious warning signs appear.

Հաճախակի տրվող հարցեր about Spnib (Dasatinib)

Հարց 1: What is Spnib 100 mg used for?
Սպնիբ 100 մգ պարունակում է դասատինիբ, երկրորդ սերունդ BCR-ABL թիրոզին կինազի ինհիբիտոր used under specialist supervision for Philadelphia chromosome–positive քրոնիկ միելոիդ լեյկեմիա (ՔՄԼ) և Ph+ սուր լիմֆոբլաստային լեյկոզ (ALL), տեղական հաստատումների և ուղեցույցների համաձայն։.

Հարց 2: How should I take Spnib 100 mg tablets?
Spnib 100 mg dasatinib tablets are usually taken once daily, swallowed whole with water. You should follow the exact dose and timing given by your hematologist and avoid crushing or chewing the tablets. If you miss a dose, follow the instructions in your product leaflet or contact your clinic rather than doubling up the next day.

Հարց 3: Will I need regular blood tests while on dasatinib?
Yes. Dasatinib can cause myelosuppression and other laboratory changes, so regular full blood counts and chemistry tests are essential, especially early in treatment. Your team will use these results to adjust your dose, pause therapy or provide supportive care if necessary.

Հարց 4: Can Spnib 100 mg interact with other medicines?
Dasatinib is metabolised by CYP3A4 and can interact with many medicines, including certain antifungals, antibiotics, antivirals, anticonvulsants and stomach acid–reducing drugs. You should provide a full list of all prescription, over-the-counter and herbal products to your specialist, and never start or stop any medicine without checking for potential interactions.

Հարց 5: How long will I need to stay on Spnib 100 mg?
Treatment duration with Spnib 100 mg dasatinib tablets is highly individual. Many patients remain on therapy for years to maintain deep molecular responses, while others may switch TKIs or change strategy if responses are suboptimal or side effects are problematic. Your hematologist will review your response milestones and overall health to decide whether to continue, adjust or change treatment over time.